CN107382897B - Intermediate of betrixaban and preparation method and application thereof - Google Patents
Intermediate of betrixaban and preparation method and application thereof Download PDFInfo
- Publication number
- CN107382897B CN107382897B CN201710557504.7A CN201710557504A CN107382897B CN 107382897 B CN107382897 B CN 107382897B CN 201710557504 A CN201710557504 A CN 201710557504A CN 107382897 B CN107382897 B CN 107382897B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- reaction
- acid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229950011103 betrixaban Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 title abstract description 35
- 238000006243 chemical reaction Methods 0.000 claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 25
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- UMKSAURFQFUULT-UHFFFAOYSA-N 2-Amino-5-methoxybenzoic acid Chemical compound COC1=CC=C(N)C(C(O)=O)=C1 UMKSAURFQFUULT-UHFFFAOYSA-N 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 11
- 230000009471 action Effects 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- DTSJEZCXVWQKCL-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-(5-chloropyridin-2-yl)-2-[[4-(n,n-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide Chemical compound OC(=O)\C=C/C(O)=O.C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 DTSJEZCXVWQKCL-BTJKTKAUSA-N 0.000 claims description 8
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 8
- 229940126214 compound 3 Drugs 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 8
- 238000007112 amidation reaction Methods 0.000 claims description 7
- ADCUEPOHPCPMCE-UHFFFAOYSA-N 4-cyanobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C=C1 ADCUEPOHPCPMCE-UHFFFAOYSA-N 0.000 claims description 6
- 150000001718 carbodiimides Chemical class 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000007363 ring formation reaction Methods 0.000 claims description 6
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 6
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 5
- MAXBVGJEFDMHNV-UHFFFAOYSA-N 5-chloropyridin-2-amine Chemical compound NC1=CC=C(Cl)C=N1 MAXBVGJEFDMHNV-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 150000007530 organic bases Chemical group 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 150000001266 acyl halides Chemical class 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical group Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 238000007142 ring opening reaction Methods 0.000 claims description 3
- WLVXSPDQBQUJMB-UHFFFAOYSA-N CNC.[Na] Chemical group CNC.[Na] WLVXSPDQBQUJMB-UHFFFAOYSA-N 0.000 claims description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 abstract description 9
- 239000002994 raw material Substances 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- -1 benzoxazinone compound Chemical class 0.000 description 13
- 238000003756 stirring Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 7
- LXFSCSJMDZZGDN-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C#N)C=C1 LXFSCSJMDZZGDN-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000003513 alkali Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010074860 Factor Xa Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- VKBARRDTXUEGGY-UHFFFAOYSA-N O1CCCC1.[Na].CNC Chemical compound O1CCCC1.[Na].CNC VKBARRDTXUEGGY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 206010047249 Venous thrombosis Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- UMOIFGNHLTVCEK-UHFFFAOYSA-N (4-cyanophenyl) carbonochloridate Chemical compound ClC(=O)OC1=CC=C(C#N)C=C1 UMOIFGNHLTVCEK-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 2
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 description 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 2
- YLHOUEPSWORKCF-UHFFFAOYSA-N N=C=O.N#CC1=CC=CC=C1 Chemical compound N=C=O.N#CC1=CC=CC=C1 YLHOUEPSWORKCF-UHFFFAOYSA-N 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229960003886 apixaban Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229960000622 edoxaban Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- GSJRUEBQWPLHSN-UHFFFAOYSA-N n-methylmethanamine;oxolane Chemical compound CNC.C1CCOC1 GSJRUEBQWPLHSN-UHFFFAOYSA-N 0.000 description 2
- 229940127216 oral anticoagulant drug Drugs 0.000 description 2
- 238000011946 reduction process Methods 0.000 description 2
- 229960001148 rivaroxaban Drugs 0.000 description 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- MUKRWNCEVRELII-UHFFFAOYSA-N 5-cyclononyl-2,3,4,6,7,8-hexahydro-1,5-diazonine Chemical compound C1CCCCC(CCC1)N1CCCC=NCCC1 MUKRWNCEVRELII-UHFFFAOYSA-N 0.000 description 1
- URADKXVAIGMTEG-UHFFFAOYSA-N 5-methoxy-2-nitrobenzoic acid Chemical compound COC1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 URADKXVAIGMTEG-UHFFFAOYSA-N 0.000 description 1
- WQNLAJFNMWQDQA-UHFFFAOYSA-N C(#N)C1=CC=CC=C1.C(O)(=O)Cl Chemical compound C(#N)C1=CC=CC=C1.C(O)(=O)Cl WQNLAJFNMWQDQA-UHFFFAOYSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 238000003482 Pinner synthesis reaction Methods 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 102100038182 Vitamin K-dependent gamma-carboxylase Human genes 0.000 description 1
- OLUQNHZGDAZRKM-UHFFFAOYSA-N [Li].CNC Chemical compound [Li].CNC OLUQNHZGDAZRKM-UHFFFAOYSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical class N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- JLSSWDFCYXSLQX-UHFFFAOYSA-N ethyl 4-cyanobenzoate Chemical compound CCOC(=O)C1=CC=C(C#N)C=C1 JLSSWDFCYXSLQX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 108010013113 glutamyl carboxylase Proteins 0.000 description 1
- 125000005252 haloacyl group Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl chloride Substances ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000007395 thrombosis prophylaxis Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an intermediate of betrixaban and a preparation method and application thereof, wherein the intermediate has a structure shown in formula I, can be efficiently synthesized by cheap and easily-obtained raw materials, and meanwhile, when the raw materials are used for synthesizing betrixaban, the subsequent reaction yield is high, the post-treatment is simple, the purity of the obtained product is high, and the intermediate has a relatively high industrial application prospect.
Description
Technical Field
The invention belongs to the technical field of organic chemistry and pharmaceutical chemistry, and relates to an intermediate of betrixaban, and a preparation method and application thereof. More particularly, the present invention relates to a benzoxazinone compound and a preparation method thereof.
Background
Venous and arterial thromboembolic diseases have a significant impact on human morbidity and mortality, and therefore, new therapies for thromboembolism remain a major focus of drug development. In the coagulation cascade, vitamin K is an important cofactor for liver gamma-glutamyl carboxylase, which can add activated carboxylic acid esters to a series of proteases, such as factors II, VII, IX or X. Activated factor X dominates the coagulation cascade, and it communicates the intrinsic and extrinsic coagulation pathways, a rate-limiting step in thrombin generation. Thus, the effect of activated factor X on the coagulation cascade can be measured by its time to prolong prothrombin, thereby indicating its activation of the extrinsic pathway; it can also be measured by the time it activates a portion of thromboplastin, thereby indicating its activation of intrinsic pathways. The sand class of oral anticoagulants are coagulation factor Xa inhibitors, and are also the only oral anticoagulants except warfarin. Currently, the marketed sabainide anticoagulants mainly include rivaroxaban, apixaban and edoxaban.
Betrixaban, also known as betrixaban, is mainly used for the prevention and treatment of deep venous thrombosis and prevention of postoperative venous thrombosis and pulmonary embolism, and has the chemical name: n- (5-chloro-2-pyridyl) -2- [4- (N, N-dimethylcarbamimidoyl) benzoylamino ] -5-methoxybenzamide maleate with the structural formula shown in the specification.
Betriciban maleate
Betrixaban is a new family of coagulation factor Xa inhibitors developed by Millennium pharmaceuticals (Millennium) in the united states. In 2014, bordeaux Pharmaceuticals (Portola Pharmaceuticals) acquired exclusive rights to global development and commercialization of betrixaban from wutian (acquired millennium Pharmaceuticals). Currently, betrixaban has filed an NDA application in the united states, with FDA approval for marketing on 6/23 of 2017; betrixaban has also completed clinical studies in china and is expected to submit new drug applications for marketing in a short time. Betrixaban as a new member of the sandban class of drugs has its own unique advantages in clinical terms compared to marketed sandban drugs: its clinical research on thrombus prevention of acute patients reaches a main effective endpoint. Because clinical studies of rivaroxaban, apixaban and edoxaban in this respect have not been successful; moreover, there is currently no effective anticoagulant approved or recommended by guidelines for venous thrombosis prevention in acute medical patients; therefore, betrixaban is highly likely to form a monopoly in the prevention of venous thrombosis in acute patients.
Patent documents WO2008057972, WO2011084519, CN201610178032 and the like successively disclose preparation methods of betrixaban.
The patent document WO2008057972 of the original research company originally discloses a preparation method of betrixaban, and a synthetic route is shown as a route one. Route one using 5-methoxy-2-nitrobenzoic acid as raw material in POCl3Carrying out amidation reaction on acyl chloride prepared in situ by Vilsmeier reaction and 2-amino-5-chloropyridine under the action to obtain a compound 1; hydrogenating and reducing the compound 1 to obtain a compound 2; an intermediate 3 of the compound 2 and p-cyanobenzoyl chloride through acylation reaction; then, the intermediate 3 is subjected to a Pinner reaction in a high-concentration hydrogen chloride methanol solution, and then the betrixaban free alkali 4 is prepared through a dimethylaminolysis reaction; the free alkali and maleic acid form salt to obtain the betrixaban maleate.
Route one
In the first route, a virulent reagent POCl is used3The process is not friendly, and the three wastes treatment burden is heavy, which is not beneficial to the industrialized production. In the first route, a pressure hydrogenation reduction reaction is also used, so that the risk of EHS is increased, chlorine atoms on pyridine rings are easy to be hydrogenated and removed in the hydrogenation process, the content of each component in the reaction process needs to be monitored in real time, and the industrialization difficulty is increased.
In another patent document WO2011084519, the original company has adjusted the process described in route one, as shown in route two. Ethyl p-cyanobenzoate is used as a starting material, an amidino compound 5 is prepared by aminolysis with a dimethylamine lithium reagent, the compound 5 is hydrolyzed under an alkaline condition to prepare corresponding acid 6, the corresponding acid 6 and an intermediate 2 in the first route are subjected to condensation reaction to prepare free alkali 4, and finally salification is carried out to obtain the betrixaban maleate.
Route two
Route two also uses the same intermediate 2, so hydrogenation reduction process is still not avoided; further, the condensation reaction of the compound 2 with the compound 6 requires the reaction system to be anhydrous. In order to ensure the complete condensation reaction, a large amount of condensation agent 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC & HCl) is required to be used in the reaction process, and the by-product urea of EDC has good water solubility, but is difficult to degrade, so that the difficulty in wastewater treatment is increased.
Another process route for synthesizing betrixaban is disclosed in patent document CN201610178032, by the university of chongqing medicine, as shown in route three. Although the hydrogenation reduction process is avoided in the third route, the process does not effectively shorten the synthesis route of betrixaban, the overall yield is not ideal, the stability of the adopted starting materials is poor, and the commercial sources are not easily obtained.
Route three
Based on the defects of the preparation method of the betrixaban, the inventor researches the preparation method of the betrixaban and the key intermediate thereof, and develops a new method for preparing the betrixaban key intermediate. And the synthetic route for preparing the betrixaban is effectively shortened, and the synthetic cost of the betrixaban is reduced.
Disclosure of Invention
The invention provides a new betrixaban intermediate and a preparation method thereof, and also provides a new process route for synthesizing betrixaban, wherein the process has the advantages of mild reaction, simple and convenient operation, environmental friendliness and high yield, and is suitable for industrial production.
An intermediate of betrixaban has a structure shown in formula I:
the invention also provides a synthesis method of the compound shown in the formula I, which is characterized in that 5-methoxy-2-aminobenzoic acid or ester thereof and 4-cyanobenzene derivative are used as raw materials, and the compound shown in the formula I is prepared through amidation and cyclization reactions.
Wherein R is1Independently of each other is H atom, C1-C2Alkyl radical, C2-C3Alkenyl, substituted or unsubstituted phenyl, the substituents on the phenyl being selected from nitro, alkyl, alkoxy or halogen; r2Independently a carboxyl, haloacyl, isocyanato or chloroformyloxy group.
Further, the preparation method of the compound of formula I is preferably as follows:
5-methoxy-2-aminobenzoic acid or ester thereof and 4-cyanobenzoic acid or acyl halide thereof are subjected to amidation reaction under the action of an acid-binding agent to obtain a compound shown as a formula II, the compound shown as the formula II is subjected to cyclization under a heating condition without separation and purification, and is cooled and crystallized to obtain the compound shown as the formula I.
Scheme one
Wherein R is1Independently of each other is H atom, C1-C4Alkyl radical, C2-C4Alkenyl, substituted or unsubstituted phenyl, the substituents on the phenyl being selected from nitro, alkyl, alkoxy or halogen; r3independently-OH, a chlorine atom or a bromine atom;
the acid-binding agent in the first scheme is an organic base reagent selected from tertiary amine organic bases, preferably pyridine, triethylamine, diisopropylethylamine and N-methylmorpholine;
in the first scheme, the heating reaction temperature is 80-120 ℃, and preferably 110-120 ℃; the reaction time is 1 to 8 hours, preferably 2 hours;
the cooling crystallization in the first scheme has the cooling end point temperature of 0-30 ℃, and preferably 0-10 ℃.
In the first embodiment, the reaction solvent is preferably toluene.
Further, the preparation of said compounds of formula i, preferably the following scheme two:
5-methoxy-2-aminobenzoic acid or ester thereof and 4-cyanobenzoic acid or acyl halide thereof are subjected to amidation reaction under the action of chloroformate and acid-binding agent to obtain the compound shown as the formula II, and the compound shown as the formula II is subjected to dehydration cyclization in the presence of a condensing agent without separation and purification to obtain the compound shown as the formula I.
Scheme two
Wherein R is1Independently of each other is H atom, C1-C4Alkyl radical, C2-C4Alkenyl, substituted or unsubstituted phenyl, the substituents on the phenyl being selected from nitro, alkyl, alkoxy or halogen; r3independently-OH, a chlorine atom or a bromine atom; r4Independently is C1-C4Alkyl of (C)2-C4Alkenyl, substituted or unsubstituted phenyl, the substituents on the phenyl being selected from nitro, alkyl, alkoxy or halogen;
the acid-binding agent in the second scheme is an organic base reagent selected from tertiary amine organic bases, preferably pyridine, triethylamine, diisopropylethylamine and N-methylmorpholine;
the condensing agent in the second scheme is selected from a triphenylphosphine/carbon tetrachloride composition, a carbodiimide reagent or a carbodiimide reagent/1-hydroxybenzotriazole composition;
the carbodiimide reagent described in scheme two is preferably 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride or dicyclohexylcarbodiimide;
in scheme two, the reaction solvent is preferably dichloromethane.
Further, the preparation of said compounds of formula i, is preferably as follows scheme three:
5-methoxy-2-aminobenzoic acid or ester thereof and 4-cyanobenzene isocyanate or 4-cyanobenzene chloroformate are subjected to amidation and cyclization reaction under the action of an acid-binding agent to prepare the compound shown in the formula I.
Scheme three
Wherein R is1Independently of each other is H atom, C1-C4Alkyl radical, C2-C4Alkenyl, substituted or unsubstituted phenyl, the substituents on the phenyl being selected from nitro, alkyl, alkoxy or halogen; r5Independently is-NCO or-OCOCl;
the acid-binding agent in the third scheme is an organic base reagent, preferably pyridine, triethylamine, diisopropylethylamine and N-methylmorpholine; the reaction temperature in the third scheme is 20-80 ℃; the reaction time in the third scheme is 5-24 hours;
in the third embodiment, the reaction solvent is preferably DMF or pyridine, and when pyridine is used as the solvent, pyridine is also used as the acid-binding agent.
The betrixaban intermediate compound shown in the formula I can be used for synthesizing a compound shown in the formula 3.
The compound of the intermediate formula I of the betrixaban can also be used for synthesizing the betrixaban and is carried out according to the following steps:
step A: reacting the compound shown in the formula I with 5-chloro-2-aminopyridine under the action of a catalyst, and carrying out ring opening to obtain a compound 3;
and B: preparing a compound 4 under the action of the compound 3 and a dimethylamine metal reagent;
and C: salifying the compound 4 and maleic acid to prepare Betrixaban maleate;
the reaction equation is as follows:
in the application, the catalyst in the step A is an alkali reagent, preferably triethylene diamine, 1, 8-diazabicycloundec-7-ene and 1, 5-diazabicyclonon-5-ene; in the application, the dimethylamine metal reagent in the step B is preferably dimethylamine sodium solution.
In the step A, the reaction solvent is dichloromethane, and after the reaction is finished, the solid product can be separated out by directly cooling to obtain the ring-opening intermediate.
The "alkyl group" in the present invention means a group formed by a straight-chain or branched saturated aliphatic hydrocarbon having one hydrogen atom removed; alkyl groups of 1 to 4 carbon atoms are preferred, including but not limited to methyl, ethyl, t-butyl, and the like.
In the present invention, alkoxy means a group formed by a straight-chain or branched saturated aliphatic alcohol having one hydrogen atom of a hydroxyl group removed; preferably 1-4, including but not limited to methoxy, ethoxy, propoxy, and the like
In the present invention, halogen means F, Cl, Br or I, preferably F, Cl or Br.
The "alkenyl group" in the present invention means a group formed by losing one hydrogen atom from a straight-chain or branched unsaturated aliphatic hydrocarbon having a carbon-carbon double bond; alkenyl of 2 to 4 carbon atoms is preferred, including but not limited to vinyl, allyl, and the like.
The "substituted phenyl group" in the present invention refers to a phenyl group formed by substituting a hydrogen atom on a benzene ring with one or more groups, including but not limited to 4-nitrophenyl group, 2-chloro-4-nitrophenyl group, and the like.
Compared with the prior art, the invention has the beneficial effects that:
(1) the method is used for synthesizing the intermediate of the betrixaban, is convenient to synthesize, has cheap and easily obtained raw materials, and has high ring closing yield;
(2) when the intermediate is used for synthesizing a subsequent intermediate, the reaction condition is mild, strong alkali potassium tert-butoxide and the like are not needed, the yield and the purity are high, and the cost of the whole route is effectively reduced.
(3) When the intermediate is used for synthesizing the betrixaban, compared with the prior art, the intermediate obviously reduces the synthesis steps, shortens the synthesis route and reduces the cost for synthesizing the betrixaban.
Detailed Description
The following specific examples are presented to enable those skilled in the art to make a complete understanding of the invention and are not intended to limit the invention in any way.
In the following examples, all temperatures are in degrees celsius unless otherwise indicated; the room temperature is 20-30 ℃ unless otherwise indicated; unless otherwise indicated, various starting materials and reagents were obtained commercially and were used without further purification; unless otherwise indicated, each solvent is a technical grade solvent and is used without further treatment; unless otherwise indicated, commercial manufacturers include, but are not limited to, Hangzhou chemical reagents, national drug reagents, and the like.
Example 1: preparation of 2- (4-cyanophenyl) -6-methoxybenzo [ d ] -1, 3-oxazin-4-one (I)
To a 150mL reaction flask were added 5.0g of 5-methoxy-2-aminobenzoic acid (29.9mmol) and 25mL of dichloromethane, and after stirring to dissolve the clear, 5.0mL of Triethylamine (TEA) (36.1mmol) was added. The mixed solution is cooled to 0-10 ℃, and 5.9g of 4-cyanobenzoyl chloride is dripped into the mixed solution(35.6mmol) in toluene (25mL), and the reaction mixture was warmed to room temperature and stirred for 8 hours. After TLC detection of 5-methoxy-2-aminobenzoic acid reaction, 35mL of purified water was added to wash the reaction solution. The organic layer was separated, heated to toluene reflux temperature and stirred for 2 hours. After TLC detection reaction is completed, the reaction liquid is slowly cooled to 0-10 ℃, and precipitated solid is filtered, washed and dried to obtain 7.36g of the compound I, wherein the yield is 88.6%, and the purity is 99.8%.1H-NMR(500MHz,CDCl3):δ8.12(d,2H,J=7.8Hz),7.83(d,2H,J=7.8Hz),7.74(s,1H),7.40(d,1H,J=8.1Hz),7.31(d,1H,J=8.1Hz),3.86(s,3H)。13C-NMR(125MHz,CDCl3):δ159.1,157.8,149.6,146.6,136.5,133.6,129.5,128.5,126.6,125.3,118.4,114.8,114.7,114.5,110.1,55.6。ESI-MS:m/z279.32[M+H]+。
Example 2: preparation of 2- (4-cyanophenyl) -6-methoxybenzo [ d ] -1, 3-oxazin-4-one (I)
A100 mL reaction flask was charged with 2.0g of 5-methoxy-2-aminobenzoic acid (12.0mmol), 10mL of dichloromethane, and 1mL of methyl morpholine (NMM), stirred to dissolve, cooled to 0-10 deg.C, and to the mixture was added 1.76g of 4-cyanobenzoic acid (12.0mmol) and 1.8g of isobutyl chloroformate. The reaction solution was warmed to room temperature and stirred for 5 hours. Detecting 5-methoxy-2-aminobenzoic acid by TLC, concentrating the reaction solution at 35-45 deg.C under reduced pressure to dry, adding 10mL carbon tetrachloride (CCl) into the slurry4) And 3.46g of triphenylphosphine (13.2mmol), reacting at 30-35 ℃ for 5 hours, after TLC detection reaction, adding 50mL of n-hexane into the reaction solution, precipitating suspended matters, stirring for 30 minutes, filtering, and drying the solid to obtain 2.84g of a compound I, wherein the yield is 85.2%, and the purity is 99.6%.
Example 3: preparation of 2- (4-cyanophenyl) -6-methoxybenzo [ d ] -1, 3-oxazin-4-one (I)
To a 100mL reaction flask were added 2.0g of 5-methoxy-2-aminobenzoic acid (12.0mmol), 10mL of dichloromethane, and 5.1g of 1-ethyl- (3-dimethylaminopropyl) carbonyldiimine hydrochloride (EDC) (26.4mmol), the mixture was cooled to 0-10 ℃ after stirring to dissolve the supernatant, and to the mixture was added 1.76g of 4-cyanobenzoic acid (12.0mmol) and 1.9g of 1-hydroxybenzotriazole (14.4mmol) (HOBT). The reaction mixture was warmed to room temperature and stirred for 12 hours. After TLC detection of 5-methoxy-2-aminobenzoic acid reaction, 50mL of n-hexane was added to the reaction solution, suspended matter was precipitated and stirred for 30 minutes, and then filtration was carried out, and the solid was dried to obtain 2.83g of compound I, with a yield of 84.8% and a purity of 99.3%.
Example 4: preparation of 2- (4-cyanophenyl) -6-methoxybenzo [ d ] -1, 3-oxazin-4-one (I)
2.0g of 5-methoxy-2-aminobenzoic acid (12.0mmol), 10mL of DMF and 1mL of pyridine were put in a 100mL reaction flask, and after stirring to dissolve, 1.73g of 4-cyanobenzeneisocyanate (12.0mmol) was added to the mixture. The reaction solution was heated to 80 ℃ and stirred for 5 hours. After TLC detection of 5-methoxy-2-aminobenzoic acid reaction, the reaction liquid was cooled to room temperature, 50mL of purified water was added dropwise to the reaction mixture, suspended matter was precipitated and stirred for 30 minutes, filtration was carried out, and the solid was dried to obtain 2.77g of compound I, with a yield of 83% and a purity of 99.5%.
Example 5: preparation of 2- (4-cyanophenyl) -6-methoxybenzo [ d ] -1, 3-oxazin-4-one (I)
2.0g of 5-methoxy-2-aminobenzoic acid (12.0mmol), 10mL of DMF and 1mL of pyridine were put in a 100mL reaction flask, stirred to dissolve, cooled to 0-10 ℃ and 2.61g of 4-cyanophenyl chloroformate (14.4mmol) was added to the mixture. The reaction mixture was warmed to room temperature and stirred for 8 hours. After TLC detection of 5-methoxy-2-aminobenzoic acid reaction, 50mL of purified water was added dropwise to the reaction mixture, suspended matter was precipitated and stirred for 30 minutes, and then filtration was carried out, and the solid was dried to obtain 2.72g of compound I, with a yield of 81.5% and a purity of 99.4%.
Example 6: preparation of 2- (4-cyanophenyl) -6-methoxybenzo [ d ] -1, 3-oxazin-4-one (I)
To a 150mL reaction flask were added 5.0g of 5-methoxy-2-aminobenzoic acid (29.9mmol) and 30mL of pyridine, stirred to dissolve and clear, cooled to 0-10 deg.C, and 5.9g of 4-cyanobenzoyl chloride (35.6mmol) was added to the mixture. The reaction solution was warmed to room temperature and stirred for 24 hours. After TLC detection of 5-methoxy-2-aminobenzoic acid reaction, pyridine was concentrated to dryness under reduced pressure at 60 deg.C, and the obtained slurry was separated and purified by silica gel column chromatography to obtain 6.47g of compound I, with a yield of 77.9% and a purity of 99.3%.
Example 7: preparation of 2- (4-cyanophenyl) -6-methoxybenzo [ d ] -1, 3-oxazin-4-one (I)
A100 mL reaction flask was charged with 2.0g of 5-methoxy-2-aminobenzoic acid (12.0mmol), 10mL of DCM and 1mL of Diisopropylethylamine (DIPEA), stirred to dissolve and clear, cooled to 0-10 ℃ and 2.61g of 4-cyanophenyl chloroformate (14.4mmol) was added to the mixture. The reaction solution is heated to 40-45 ℃ and stirred and refluxed for 6 hours. After TLC detection of 5-methoxy-2-aminobenzoic acid reaction, the reaction liquid is cooled to 0-10 ℃, 50mL of n-hexane is dripped into the reaction mixed liquid, suspended matters are separated out and stirred for 30 minutes, filtration is carried out, and the solid is dried to obtain 2.75g of the compound I, wherein the yield is 82.4% and the purity is 99.6%.
Example 8: preparation of N- (5-chloro-2-pyridyl) -2- [ (4-cyanobenzoyl) amino ] -5-methoxybenzamide (3)
A150 mL reaction flask was charged with 5g of Compound I (18.0mmol) and 2.76g of 5-chloro-2-aminopyridine, and 30mL of dichloromethane was added and the solution was stirred. The mixture was cooled to 0-10 ℃ and 2.0g of triethylenediamine (18mmol) was added to the cooled solution. Heating the reaction solution to 35-40 ℃, refluxing and stirring for 4 hours, detecting by TLC that the compound I is reacted, cooling the reaction solution to 0-10 ℃, separating out solids, performing suction filtration and drying to obtain 6.42g of the compound 3, wherein the yield is 87.7 percent, and the purity is 99.7 percent.1H-NMR(500MHz,DMSO-d6):δ11.1(s,1H),10.9(s,1H),8.42(d,1H,J=2.0Hz),8.11(d,1H,J=9.0Hz),8.04~8.01(m,4H),7.95(d,2H,J=8.5Hz),7.42(d,1H,J=2.5Hz),7.18~7.15(m,1H),3.84(s,3H)。
Example 9: preparation of N- (5-chloro-2-pyridyl) -2- [ (4-cyanobenzoyl) amino ] -5-methoxybenzamide (3)
A150 mL reaction flask was charged with 5g of Compound I (18.0mmol) and 2.76g of 5-chloro-2-aminopyridine, and 30mL of dichloromethane was added and the solution was stirred. The mixture was cooled to 0-10 ℃ and 2.74g1, 8-diazabicycloundecen-7-ene (18mmol) were added to the cooled solution. Heating the reaction solution to 35-40 ℃, refluxing and stirring for 5 hours, detecting by TLC that the compound I is reacted, cooling the reaction solution to 0-10 ℃, separating out solids, performing suction filtration and drying to obtain 6.44g of compound 3, wherein the yield is 88%, and the purity is 99.5%.
Example 10: preparation of N- (5-chloro-2-pyridinyl) -2- [ [4- [ methoxyamidino ] benzoyl ] amino ] -5-methoxybenzamide (4)
30mL of 2mol/L dimethylamine tetrahydrofuran solution (60mmol) is cooled to 0-10 ℃, 1.2g (50mmol) of sodium hydride is added in batches under stirring, and the temperature is controlled at 0-10 ℃ to obtain the dimethylamine sodium tetrahydrofuran solution for later use.
In a 150mL reaction flask4.0g of Compound 3(9.8mmol) and 20mL of tetrahydrofuran were added, stirred and dissolved, the temperature was controlled at 0-10 ℃ and the above dimethylamine sodium tetrahydrofuran solution was added dropwise. After the dropwise addition, the temperature is raised to room temperature and the reaction is stirred. After TLC monitoring reaction, 2mol/L dilute hydrochloric acid solution is added into the reaction solution dropwise, pH value is adjusted to 2-3, tetrahydrofuran is removed by decompression and concentration at 45 ℃, and the obtained suspended substance is filtered. Transferring the wet cake to a 150mL reaction bottle, adding 30mL acetone, uniformly stirring, adding triethylamine to adjust the pH value to 7-8, filtering, and drying to obtain 3.61g of betrixaban free base, wherein the yield is 81.7%, and the purity is 99.8%.1H-NMR(500MHz,DMSO-d6):δ11.1(s,1H),11.0(s,1H),9.38(s,1H),9.17(s,1H),8.41(d,1H,J=2.5Hz),8.10~8.07(m,3H),7.98(d,1H,J=9.0Hz),7.96~7.94(m,1H),7.72(d,2H,J=8.5Hz),7.42(d,1H,J=2.5Hz),7.19~7.16(m,1H),3.86(s,3H),3.22(s,3H),2.98(s,3H)。
Example 11: preparation of N- (5-chloro-2-pyridinyl) -2- [ [4- [ methoxyamidino ] benzoyl ] amino ] -5-methoxybenzamide (4)
Cooling 15mL of 2mol/L dimethylamine tetrahydrofuran solution to 0-10 ℃, slowly dripping 12.5mL of 2mol/L bis (trimethylsilyl) amino sodium (NaHMDS) while stirring, and controlling the temperature at 0-10 ℃ to obtain the dimethylamine sodium tetrahydrofuran solution for later use.
A150 mL reaction flask was charged with 2.0g of Compound 3(4.9mmol) and 10mL of tetrahydrofuran, stirred to dissolve, the temperature was controlled at 0-10 deg.C, and the above dimethylamine sodium tetrahydrofuran solution was added dropwise. After the dropwise addition, the temperature is raised to room temperature and the reaction is stirred. After TLC monitoring reaction, 2mol/L dilute hydrochloric acid solution is added into the reaction solution dropwise, pH value is adjusted to 2-3, tetrahydrofuran is removed by decompression and concentration at 45 ℃, and the obtained suspended substance is filtered. Transferring the wet cake to a 100mL reaction bottle, adding 15mL acetone, uniformly stirring, adding triethylamine to adjust the pH value to 7-8, filtering, and drying to obtain 1.56g of betrixaban free base, wherein the yield is 70.6%, and the purity is 99.6%.
Example 12: preparation of N- (5-chloro-2-pyridinyl) -2- [ [4- [ methoxyamidino ] benzoyl ] amino ] -5-methoxybenzamide maleate (Betrixaban)
A100 mL reaction flask was charged with 3.0g (6.64mmol) of free base, 40mL of 80% aqueous ethanol (volume fraction), stirred at room temperature for 15 minutes, and 1.6g (13.8mmol) of maleic acid in 80% aqueous ethanol (10mL) was added dropwise. After the completion of the dropwise addition, the mixture was stirred at room temperature for 2.5 hours, 50mL of purified water was added to the reaction mixture, and the reaction mixture was concentrated under reduced pressure at 45 ℃ to about 50mL to precipitate a pale yellow solid. The suspension was cooled from a temperature of 45 ℃ to 10 ℃ at a cooling rate of 1 ℃/5 min. After cooling to the end point temperature, stirring for 15 minutes at 15 ℃, filtering, and drying to obtain 3.54g of light yellow solid compound, namely the betrixaban maleate, with the yield of 78.6% and the purity of 99.9%.1H-NMR(500MHz,DMSO-d6):δ11.1(s,1H),11.0(s,1H),9.35(s,1H),8.98(s,1H),8.42(d,1H,J=2.5Hz),8.10~8.06(m,3H),7.99(d,1H,J=9.0Hz),7.96~7.93(m,1H),7.73(d,2H,J=8.5Hz),7.42(d,1H,J=3.0Hz),7.19~7.17(m,1H),3.85(s,3H),3.21(s,3H),2.98(s,3H)。13C-NMR(125MHz,DMSO-d6):δ167.7,167.6,164.6,164.3,156.1,151.0,146.9,138.3,138.1,136.6,132.7,130.9,129.1,128.3,127.1,126.4,125.3,118.7,116.7,114.4,56.1,42.3。
While the method of the present invention has been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the relevant art that the techniques of the present invention may be practiced and applied with little or no adaptation, modification, or combination of the methods and applications described herein as appropriate within the spirit and scope of the present invention. The skilled person can also use the present disclosure to realize the above by appropriately modifying the process parameters. It is expressly intended that all such modifications and adaptations which are apparent to those skilled in the art are intended to be included within the present invention.
Claims (3)
1. The preparation method of the betrixaban maleate is characterized by comprising the following steps:
step A: reacting the compound shown in the formula I with 5-chloro-2-aminopyridine under the action of a catalyst, and carrying out ring opening to obtain a compound 3;
and B: preparing a compound 4 under the action of the compound 3 and a dimethylamine metal reagent;
and C: salifying the compound 4 and maleic acid to prepare Betrixaban maleate;
the reaction equation is as follows:
wherein,
the catalyst in the step A is selected from triethylene diamine and 1, 8-diazabicycloundecen-7-ene;
in step B, the dimethylamine metal reagent is dimethylamine sodium solution.
2. The process for the preparation of betrixaban maleate, as claimed in claim 1, further comprising the preparation of a compound of formula i:
carrying out amidation reaction on 5-methoxy-2-aminobenzoic acid or ester thereof and 4-cyanobenzoic acid or acyl halide thereof under the action of an acid-binding agent to obtain a compound shown as a formula II, carrying out cyclization on the compound shown as the formula II under a heating condition without separation and purification, and cooling and crystallizing to obtain a compound shown as a formula I;
wherein,
R1independently of each other is H atom, C1-C4Alkyl radical, C2-C4Alkenyl, substituted phenyl or unsubstituted phenyl, the substituents on the phenyl being selected from nitro, alkyl, alkoxy or halogen; r3independently-OH, a chlorine atom or a bromine atom;
the acid-binding agent is an organic base reagent selected from pyridine, triethylamine, diisopropylethylamine and N-methylmorpholine;
the heating reaction temperature is selected from 80-120 ℃; the reaction time is selected from 1-8 hours;
the cooling crystallization is carried out, wherein the cooling end point temperature is selected from 0-30 ℃.
3. The process for the preparation of betrixaban maleate, as claimed in claim 1, further comprising the preparation of a compound of formula i:
carrying out amidation reaction on 5-methoxy-2-aminobenzoic acid or ester thereof and 4-cyanobenzoic acid or acyl halide thereof under the action of chloroformate and acid-binding agent to obtain a compound shown as a formula II, and carrying out dehydration cyclization on the compound shown as the formula II in the presence of a condensing agent without separation and purification to obtain a compound shown as a formula I;
wherein R is1Independently of each other is H atom, C1-C4Alkyl radical, C2-C4Alkenyl, substituted or unsubstituted phenyl, the substituents on the phenyl being selected from nitro, alkyl, alkoxy or halogen; r3independently-OH, a chlorine atom or a bromine atom; r4Independently is C1-C4Alkyl of (C)2-C4Alkenyl, substituted or unsubstituted phenyl, the substituents on the phenyl being selected from nitro, alkyl, alkoxy or halogen;
the acid-binding agent is an organic base reagent selected from pyridine, triethylamine, diisopropylethylamine and N-methylmorpholine;
the condensing agent is selected from a triphenylphosphine/carbon tetrachloride composition, a carbodiimide reagent or a carbodiimide reagent/1-hydroxybenzotriazole composition;
the carbodiimide reagent is selected from 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride or dicyclohexylcarbodiimide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710557504.7A CN107382897B (en) | 2017-07-10 | 2017-07-10 | Intermediate of betrixaban and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710557504.7A CN107382897B (en) | 2017-07-10 | 2017-07-10 | Intermediate of betrixaban and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107382897A CN107382897A (en) | 2017-11-24 |
CN107382897B true CN107382897B (en) | 2021-05-04 |
Family
ID=60335549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710557504.7A Active CN107382897B (en) | 2017-07-10 | 2017-07-10 | Intermediate of betrixaban and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107382897B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109180573A (en) * | 2018-09-17 | 2019-01-11 | 珠海润都制药股份有限公司 | A kind of preparation method of betrixaban intermediate |
CN109942486A (en) * | 2019-04-22 | 2019-06-28 | 浙江宏元药业股份有限公司 | A kind of new betrixaban intermediate and its preparation method and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099688A2 (en) * | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
CN101589028A (en) * | 2006-11-22 | 2009-11-25 | 味之素株式会社 | Process for production of phenylalanine derivatives having quinazolinedione skeletons and intermediates for the production |
CN103261161A (en) * | 2010-09-01 | 2013-08-21 | 博尔托拉制药公司 | Crystalline forms of a factor Xa inhibitor |
CN105622538A (en) * | 2014-10-27 | 2016-06-01 | 中国医学科学院药物研究所 | One-pot high-yielding preparation of cetilistat |
-
2017
- 2017-07-10 CN CN201710557504.7A patent/CN107382897B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099688A2 (en) * | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
CN101589028A (en) * | 2006-11-22 | 2009-11-25 | 味之素株式会社 | Process for production of phenylalanine derivatives having quinazolinedione skeletons and intermediates for the production |
CN103261161A (en) * | 2010-09-01 | 2013-08-21 | 博尔托拉制药公司 | Crystalline forms of a factor Xa inhibitor |
CN105622538A (en) * | 2014-10-27 | 2016-06-01 | 中国医学科学院药物研究所 | One-pot high-yielding preparation of cetilistat |
Non-Patent Citations (4)
Title |
---|
Alteration in DNA binding pattern of conformationally locked NC(O)N system: A spectroscopic investigation;A.B. Velappan et al.;《International Journal of Biological Macromolecules》;20160112;第85卷;第497–504页 * |
Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents;A.M. Alanazi et al.;《European Journal of Medicinal Chemistry》;20140412;第79卷;第446-454页 * |
Persistently Folded Circular Aromatic Amide Pentamers Containing Modularly Tunable Cation-Binding Cavities with High Ion Selectivity;Bo Qin, et al;《J. AM. CHEM. SOC.》;20100625;第132卷;第9564–9566页 * |
Synthesis, crystal structure and biological evaluation of substituted quinazolinone benzoates as novel antituberculosis agents targeting acetohydroxyacid synthase;W. Lu et al.;《European Journal of Medicinal Chemistry》;20150307;第94卷;第298-305页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107382897A (en) | 2017-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5588506B2 (en) | Method for synthesizing 3- (substituted dihydrogenisoindoleketone-2-yl) -2,6-piperidinedione and its intermediate | |
CN104395284A (en) | Process for preparing quinoline derivatives | |
WO2015070766A1 (en) | N-benzyl tryptanthrin derivative, and preparation method and application thereof | |
WO2007079199A2 (en) | Substituted bis-amide metalloprotease inhibitors | |
EP2722330B1 (en) | Novel method for synthesizing rivaroxaban intermediate, 4-{4-[(5s)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one | |
CN109574871B (en) | Acetaminoazobenzene derivative and preparation and application thereof | |
CN107382897B (en) | Intermediate of betrixaban and preparation method and application thereof | |
CZ2012114A3 (en) | Process for preparing rivaroxaban based on saving of 1,1?-carbonyldiimidazole | |
WO2015055127A1 (en) | (r)-praziquantel preparation method | |
JP2020528064A (en) | Process for preparing and purifying the LFA-1 antagonist refitegrass | |
CN116947963A (en) | PROTACs (human immunodeficiency Virus) based on VHL ligand targeted coronavirus 3CL protease and preparation method and application thereof | |
CN104098558B (en) | Amides compound and preparation method thereof | |
WO2015188787A1 (en) | Method for preparing oxazolidinone compound and intermediates thereof | |
CN111072660B (en) | Simple preparation method of rilibatan | |
CN107987074A (en) | A kind of synthetic method of Pradofloxacin | |
CN108191849B (en) | Preparation method of anti-epidermal growth factor receptor drug resistance mutation inhibitor, related intermediate and application | |
CN103450065A (en) | Preparation method of ezetimibe | |
CN103958466B (en) | As the nitrogenous of CRTH2 antagonist and cyclic cpds | |
CN109438347B (en) | Cyanoquinoline IDO1 inhibitor, and preparation method and application thereof | |
CN103833760B (en) | Piperazine derivative | |
KR20120129317A (en) | Manufacturing Method Of Hetero Cyclic Compound | |
CN105001200A (en) | Preparation method of anti-angiogenesis compound and intermediate thereof | |
CN106928195B (en) | A kind of synthetic method of Dabigatran etexilate key intermediate | |
CN104610133A (en) | Method for synthesizing novel anticancer medicine entinostat | |
CN105481831B (en) | A kind of method for preparing dabigatran etexilate intermediate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |